Emerging Therapeutics for Patients with Triple-Negative Breast Cancer

Purpose of review Triple negative breast cancer (TNBC) accounts for approximately 10–15% of all breast cancers and it is associated with a poor prognosis. However, recent new effective treatment strategies have improved its outcomes. The aim of this review is to provide an overview on the emerging t...

Full description

Saved in:
Bibliographic Details
Published in:Current oncology reports 2021-05, Vol.23 (5), p.57-57, Article 57
Main Authors: Agostinetto, Elisa, Eiger, Daniel, Punie, Kevin, de Azambuja, Evandro
Format: Article
Language:English
Subjects:
1-Phosphatidylinositol 3-kinase
AKT protein
Antiandrogens
Antineoplastic Agents - therapeutic use
Breast cancer
Breast Cancer (AS Zimmer
Chemotherapy
Histone deacetylase
Humans
Immune checkpoint inhibitors
Medicine
Medicine & Public Health
Molecular Targeted Therapy - methods
Neoadjuvant Therapy
Oncology
Patients
Phosphatidylinositol 3-Kinase - metabolism
Phosphatidylinositol 3-Kinases - metabolism
Poly(ADP-ribose) polymerase
Proto-Oncogene Proteins c-akt - metabolism
Section Editor
Topical Collection on Breast Cancer
TOR protein
Triple Negative Breast Neoplasms - drug therapy
Triple Negative Breast Neoplasms - pathology
Triple Negative Breast Neoplasms - therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose of review Triple negative breast cancer (TNBC) accounts for approximately 10–15% of all breast cancers and it is associated with a poor prognosis. However, recent new effective treatment strategies have improved its outcomes. The aim of this review is to provide an overview on the emerging therapeutics for TNBC, describing both previously approved therapies that are currently being repurposed, as well as new target therapies that may improve patient outcomes. Recent findings Emerging therapies are forthcoming in TNBC’s treatment landscape, including new post-neoadjuvant chemotherapy strategies, PARP inhibitors, immune checkpoint inhibitors, and antibody-drug conjugates. Combination of different therapies such as AKT/PI3K/mTOR-inhibitors, other immunotherapeutic agents, CDK-inhibitors, antiandrogens, antiangiogenics, and histone deacetylase inhibitors is under clinical investigation. Summary The treatment landscape for TNBC is gradually evolving towards a more personalized approach with promising expectations.
ISSN:1523-3790
1534-6269
DOI:10.1007/s11912-021-01038-6